Themenkomplex VI: Barrett-Ösophagus

H. Messmann; C. Ell; M. Fein; R. Kiesslich; M. Ortner; R. Porschen; M. Stolte

doi:10.1055/s-2005-857876

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2005; 43(2): 184-190
DOI: 10.1055/s-2005-857876

Leitlinie

Themenkomplex VI: Barrett-Ösophagus

H. Messmann, C. Ell, M. Fein, R. Kiesslich, M. Ortner, R. Porschen, M. Stolte

Abstract

Volltext

Referenzen

Literatur

1 Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 1998; 93 1028-1032
2 Sharma P, Morales T G, Sampliner R E. Short segment Barrett’s esophagus - the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 1998; 93 1033-1036
3 Eloubeidi M A, Provenzeale D. Does this patient have Barrett’s esophagus? The utility of predicting Barrett’s esophagus at the index endoscopy. Am J Gastroenterol. 1999; 94 937-943
4 Glickman J N, Wang H, Das K M. et al . Phenotype of Barrett’s esophagus and intetinal metaplasia of distal esophagus and gastroesophageal junction. Am J Surg Pathol. 2001; 25 87-94
5 McClave S A, Boyce H W Jr, Gottfried M R. Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion. Gastrointest Endosc. 1987; 33 413-416
6 de Mas C R, Kramer M, Seifert E. et al . Short Barrett: prevalence and risk factors. Scand J Gastroenterol. 1999; 34 1065-1070
7 Eisen G M, Sandler R S, Murray S. et al . The relationship between gastroesophageal reflux disease and its complications with Barrett’s esophagus. Am J Gastroenterol. 1997; 92 27-31
8 Freston J W, Malagelada J R, Petersen H. et al . Critical issues in the management of gastroesophageal reflux disease. Eur J Gasteroenterol Hepatol. 1995; 7 577-586
9 Lieberman D A, Oehlke M, Helfand M. Risk factors for Barrett’s esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol. 1997; 92 1293-1297
10 Canto M I. Staining in gastrointestinal endoscopy: the basics. Endoscopy. 1999; 31 479-486
11 Weinstein W M, Ippoliti A F. The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest Endosc. 1996; 44 91-95
12 Alikhan M, Rex D, Khan A. et al . Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999; 50 23-26
13 Reid B J, Haggitt R C, Rubin C E. et al . Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol. 1988; 19 166-178
14 Skacel M, Petras R E, Gramlich T L. et al . The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol. 2000; 95 3383-3387
15 Wo J M, Ray M B, Mayfield-Stokes S. et al . Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett’s esophagus: A preliminary study. Gastrointest Endosc. 2001; 54 294-301
16 Sharma P, Topalovski M, Mayo M S. et al . Methylene blue chromoendoscopy for detection of short-segment Barrett’s esophagus. Gastrointest Endosc. 2001; 54 289-293
17 Canto M I, Setrakian S, Willis J. et al . Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2000; 51 560-568
18 Canto M I, Setrakian S, Petras R E. et al . Methylene blue selectively stains intestinal metaplasia in Barrett’s esophagus. Gastrointest Endosc. 1996; 44 1-7
19 Kiesslich R, Hahn M, Herrmann G. et al . Screening for specialized columnar epithelium with methylene blue: chromoendoscopy in patients with Barrett’s esophagus and a normal control group. Gastrointest Endosc. 2001; 53 47-52
20 Dave U, Shousha S, Westaby D. Methylene blue staining: is it really useful in Barrett’s esophagus?. Gastrointest Endosc. 2001; 53 333-335
21 Hackelsberger A, Günther T, Schultze V. et al . Intestinal metaplasia at the gastro-oesophageal junction: Helicobacter pylori gastritis or gastro-oesophageal reflux disease?. Gut. 1998; 43 17-21
22 Morales T G, Bhattacharyya A, Johnson C. et al . Is Barrett’s esophagus associated with intestinal metaplasia of the gastric cardia?. Am J Gastroenterol. 1997; 92 1818-1822
23 Voutilainen M, Farkkila M, Juhola M. et al . Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut. 1999; 45 644-648
24 Voutilainen M, Farkkila M, Juhola M. et al . The Central Finland Endoscopy Study Group. Specialized columnar epithelium of the esophagogastric junction: prevalence and associations. Am J Gastroenterol. 1999; 94 913-918
25 Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther. 1998; 12 735-740
26 Stolte M, Meining A, Schmitz J M. et al . Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1998; 12 247-253
27 Levine D S, Haggitt R C, Blount P L. et al . An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993; 105 40-50
28 Reid B J, Blount P L, Feng Z. et al . Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000; 95 3089-3096
29 Alexander J A, Jones S M, Smith C J. et al . Usefulness of cytopathology and histology in the evaluation of Barrett’s esophagus in a community hospital. Gastrointest Endosc. 1997; 46 318-320
30 Falk G W, Chittajallu R, Goldblum J R. et al . Surveillance of patients with Barrett’s esophagus for dysplasia and cancer with balloon cytology. Gastroenterology. 1997; 112 1787-1797
31 Endlicher E, Knuechel R, Hauser T. et al . Endoscopic fluorescence detection of low and high grade dysplasia in Barrett’s oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut. 2001; 48 314-319
32 Reid B J, Levine D S, Longton G. et al . Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000; 95 1669-1676
33 Teodori L, Gohde W, Persiani M. et al . DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett’s esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry. 1998; 34 257-263
34 Falk G W, Catalano M F, Sivak M V Jr. et al . Endosonography in the evaluation of patients with Barrett’s esophagus and high-grade dysplasia. Gastrointest Endosc. 1994; 40 207-212
35 May A, Gunter E, Roth F. et al . Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut. 2004; 53 634-40
36 Messmann H, Schlottmann K. Role of endoscopy in the staging of esophageal and gastric cancer. Semin Surg Oncol. 2001; 20 78-81
37 Weston A P, Badr A S, Ruth S. et al . Prospective multivariate analysis of clinical, endoscopic, and histologicaal factors predicitve of development of Barrett’s multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol. 1999; 94 3413-3419
38 Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 1998; 93 1028-1032
39 Van der Burgh A, Dees J, Hop W C. et al . Oesophageal cancer is an uncommon cause of death in patients with Barrett’s oesophagus. Gut. 1996; 39 5-8
40 Iftikhar S Y, James P D, Steele R J. et al . Length of Barrett’s oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut. 1992; 33 1155-1158
41 Menke-Pluymers M B, Hop W C, Dees J. et al . Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer. 1993; 72 1155-1158
42 Nijhawan P K, Wang K K. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett’s esophagus. Gastrointest Endosc. 2000; 52 328-332
43 Buttar N S, Wang K K, Sebo T J. et al . Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001; 120 1630-1639
44 Faller G, Berndt R, Borchard F. et al . Working Group for Gastroenterological Pathology, German Society for Pathology. Histopathological diagnosis of Barrett’s mucosa and associated neoplasias. Results of a consensus conference of the Working Group for „Gastroenterological Pathology of the German Society for Pathology”. Pathologe. 2003; 24 9-14
45 Gimenez A, Minguela A, Parrilla P. et al . Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett’s esophagus. Cancer. 1998; 83 641-651
46 Kim R, Clarke M R, Melhem M F. et al . Expression of p53, PCNA, an C-erbB-2 in Barrett’s metaplasia and adenocarcinoma. Dig Dis Sci. 1997; 42 2463-2462
47 Weston A P, Banerjee S K, Sharma P. et al . p53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol. 2001; 96 1355-1362
48 Van Sandick J W, van Lanschot J J, Kuiken B W. et al . Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut. 1998; 43 216-222
49 Streitz J M Jr, Andrews C W Jr, Ellis F H Jr. Endoscopic surveillance of Barrett’s esophagus. Does it help?. J Thorac Cardiovasc Surg. 1993; 105 383-387
50 Fitzgerald R C, Saeed I T, Khoo D. et al . Rigorous surveillance protocol increases detection of curable cancers associated with Barrett’s esophagus. Dig Dis Sci. 2001; 46 1892-1898
51 Wright T A, Gray M R, Morris A I. et al . Cost effectiveness of detecting Barrett’s cancer. Gut. 1996; 39 574-579
52 Corley D A, Levin T R, Habel L A. et al . Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology. 2002; 122 633-640
53 Streitz J, Ellis F, Tilden R. et al . Endoscopic surveillance of Barrett’s esophagus: a cost-effectivness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol. 1998; 93 911-915
54 Soni A, Sampliner R, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost effective?. Am J Gastroenterol. 2000; 95 2086-2093
55 Eckhardt V F, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett’s esophagus: a prospective controlled investigation. Am J Med. 2001; 111 33-37
56 O’Connor J, Falk G, Richter J. The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus: report on the Cleveland Clinic Barrett’s Esophagus Registry. Am J Gastroenterol. 1999; 94 2037-2042
57 Shaheen N, Crosby M, Bozymski E. et al . Is there a publication bias in the reporting of cancer risk in Barrett’s esophagus?. Gastroenterology. 2000; 119 333-338
58 Jankowski J A, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett’s metaplasia has regional variations in the west. Gastroenterology. 2002; 122 588-590
59 Provenzale D, Schmitt C, Wong J. Barrett’s esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999; 94 2043-2053
60 Sampliner R E. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002; 97 1888-1895
61 Weston A, Krmpotich P, Cherian R. et al . Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: Comparison with traditional long segment Barrett’s esophagus. Am J Gastroenterol. 1997; 92 407-413
62 Wright T A. High-grade dysplasia in Barrett’s oesophagus. Br J Surg. 1997; 84 760-766
63 Weston A P, Sharma P, Topalovski M. et al . Long-term follow-up of Barrett’s high-grade dysplasia. Am J Gastroenterol. 2000; 95 1888-1893
64 Schnell T G, Sontag S J, Chejfec G. et al . Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001; 120 1607-1619
65 Falk G W, Rice T W, Goldblum J R. et al . Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999; 49 170-176
66 Ouatu-Lascar R, Fitzgerald R C, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology. 1999; 117 327-335
67 Sharma P, Sampliner R E, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett’s esophagus. Am J Gastroenterol. 1997; 92 582-585
68 Wilkinson S P, Biddlestone L, Gore S. et al . Regression of columnar-lined (Barrett’s) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther. 1999; 13 1205-1209
69 Gore S, Healey C J, Sutton R. et al . Regression of columnar lined (Barrett’s) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther. 1993; 7 623-628
70 Neumann C S, Iqbal T H, Cooper B T. Long term continuous omeprazole treatment of patients with Barrett’s oesophagus. Aliment Pharmacol Ther. 1995; 9 451-454
71 Peters F T, Ganesh S, Kuipers E J. et al . Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut. 1999; 45 489-494
72 Cooper B T, Neumann C S, Cox M A. et al . Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett’s oesophagus. Aliment Pharmacol Ther. 1998; 12 893-897
73 Sagar P M, Ackroyd R, Hosie K B. et al . Regression and progression of Barrett’s oesophagus after antireflux surgery. Br J Surg. 1995; 82 806-810
74 McDonald M L, Trastek V F, Allen M S. et al . Barrett’s esophagus: does an antireflux procedure reduce the need for endoscopic surveillance?. J Thorac Cardiovasc Surg. 1996; 111 1135-1138
75 Wang K K. Photodynamic therapy of Barrett’s esophagus. Gastrointest Endosc Clin N Am. 2000; 10 409-419
76 Van Laethem J L, Cremer M, Peny M O. et al . Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut. 1998; 43 747-751
77 Pereira-Lima J C, Busnello J V, Saul C. et al . High power setting argon plasma coagulation for the eradication of Barrett’s esophagus. Am J Gastroenterol. 2000; 95 1661-1668
78 Luman W, Lessels A M, Palmer K R. Failure of Nd-YAG photocoagulation therapy as treatment for Barrett’s oesophagus - a pilot study. Eur J Gastroenterol Hepatol. 1996; 8 627-630
79 Wang K K, Sampliner R E. Mucosal ablation therapy of barrett esophagus. Mayo Clin Proc. 2001; 76 433-437
80 Gossner L, May A, Stolte M. et al . KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett’s esophagus. Gastrointest Endosc. 1999; 49 8-12
81 Schulz H, Miehlke S, Antos D. et al . Ablation of Barrett’s epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc. 2000; 51 659-663
82 Pelligrinin C A, Pohl D. High grade dyplasia in Barrett’s esophagus: surveillance or operation?. J Gastrointest Surg. 2000; 4 131-134
83 Birkmeyer J D, Siewers A E, Finlayson E V. et al . Hospital volume and surgical mortality in the United States. N Engl J Med. 2002; 346 1128-1137
84 Barr H, Shepherd N A, Dix A. et al . Eradication of high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996; 348 584-585
85 Gossner L, Stolte M, Sroka R. et al . Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998; 114 448-455
86 Ackroyd R, Brown N J, Davis M F. et al . Photodynamic therapy for dysplastic Barrett’s oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut. 2000; 47 612-617
87 Overholt B F, Panjehpour M, Haydek J M. Photodynamic therapy for Barrett’s esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999; 49 1-7
88 Overholt B F, Panjehpour M, Halberg D L. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc. 2003; 58 183-188
89 Overholt B F, Lightdale C, Wang C. et al . International, multicenter, partially blinded randomised study of the efficacy of PDT using porfirmersodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE): Results of 24-month follow-up. Gastroenterology. 2003; 124 (Suppl) 151
90 Ell C, May A, Gossner L. et al . Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2000; 118 670-677
91 May A, Gossner L, Pech O. et al . Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol. 2002; 1410 1085
92 Van Laethem J L, Jagodzinski R, Peny M O. et al . Argon plasma coagulation in the treatment of Barrett’s high-grade dysplasia and in situ adenocarcinoma. Endoscopy. 2001; 33 257-261
93 Pacifico R J, Wang K K, Wongkeesong L M. et al . Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus. Clin Gastroenterol Hepatol. 2003; 1 252-257
94 Stein H J, Feith M, Mueller J. et al . Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg. 2000; 232 733-742
95 Banki F, Mason R J, DeMeester S R. et al . Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg. 2002; 236 324-335
96 Ell C, May A, Gossner L. et al . Kurative endoskopische Therapie früher Adenokarzinome der Speiseröhre. Deutsches Ärzteblatt. 2003; 21 A1438-1448
97 Sibille A, Lambert R, Souquet J C. et al . Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology. 1995; 108 337-344